PERSONAL INFORMATION

Alessandro Beghini

POSITION

Associate Professor at the University of Milan, Faculty of Medicine, (BIO/11) - Molecular Biology.

PERSONAL STATEMENT

My research interests are focused on cancer molecular genetics, and particularly on the oncogenic signaling networks involved in the development of Acute Leukemia. In this scientific context, I obtained the first evidence for the involvement of the KIT gene in the human Acute Myeloid Leukemia and particularly the peculiar association with core binding factor deranged-related neoplasms. The diagnostic/prognostic value of KIT mutations has been recognized in the definition of molecular genetic alterations affecting clinical outcome of patients (WHO, 2008). Another exciting area of research, that stems from my work on hematological malignancies, examines the gene expression programs involved in the early development of cancer stem cell. The overall focus in my ongoing research lies on the characterization of the Wnt-mediated molecular events involved in the onset and progression of cancer, with a particular focus on acute leukemia. I stably interact with haematologists within the University hospital in Milan, through the Lombardy Hematology Network (REL), and in strict collaboration with the Niguarda Cancer Center to facilitate knowledge exchange on translational medicine between academia, public health and caring sciences. My translational aims are focused to develop a better and deep diagnostic/prognostic definition, and on therapeutic implications based on cancer drug targets.

WORK EXPERIENCE

06/2001-10/2017 **Assistant Professor in Medical Genetics (MED/03) | University of Milan, Department of Biotechnology and Translational Medicine, Milan, Italy**

11/1999-05/2001 **Research Fellow | University of Milan, Department of Biology and Genetics for Medical Sciences, Milan, Italy**

EDUCATION AND TRAINING

15/04-15/05/2016 **Visiting Researcher at the Biomedical Center of Lund University**, Lund, Sweden (Prof. Thomas Laurell).

28/3-28/6/2014 **Visiting Researcher at the Department of Immunology, Genetics and Pathology SciLifeLab**, Biomedical Center, Uppsala University, Sweden (Prof. Ulf Landegren and Prof. Ola Söderberg).

05/2012 **Visiting Researcher at the Department of Immunology, Genetics and Pathology, Rudbeck laboratory**, Uppsala University, Sweden (Prof. Ulf Landegren and Prof. Mats Nilsson).

11/2011 **Visiting Researcher at the Department of Immunology, Genetics and Pathology, Rudbeck laboratory**, Uppsala University, Sweden (Prof. Mats Nilsson).

04/2005 **Visiting Researcher at the Center for Biomedical Genomics, George Mason University**-Prince William Campus (Manassas VA, USA).

02/2000 **PhD in Medical Genetics (XI cycle)**

University of Genova, Genova, Italy

- Supervisor: Professor F.Ajmar
- Thesis Title: Activating mutations of the protooncogene c-Kit in acute myeloid leukemia: role in mastocyte differentiation in vivo and in vitro

12/1994

University of Milan | Milan, Italy

MSc: Biological Sciences

Thesis Title: Characterization of a structural rearrangement of the c-fes protooncogene in high malignancy lymphomacrophagic hybrids

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1/C2	C1/C2	C1/C2	C1/C2	C1/C2

PERSONAL SKILLS

Communication skills

- Excellent communication skills acquired during my experience as university professor and scientific speaker.
-

From 1998 to the present speaker and co-rapporteur in:
• 14 Master's degree theses (4 Medicine and Surgery, 3 Biological Sciences, 6 Medical Biotechnologies, 1 Informatics)
• 2 undergraduate thesis in Medical Biotechnology
• 2 Specialization theses in Medical Genetics
• 5 PhD theses (Neurology, Psychiatry and Neurogenetics XVII cycle; Molecular Medicine-XXIV cycle; Biotechnologies applied to Medical Sciences XXV cycle; 2 Experimental Hematology XXVIII cycle).
• 2015-2017 Tutor for research grant (Dr. Lazzaroni F.)

2017-today Professor in the Degree Course in Medicine and Surgery, Polo San Paolo, teaching Molecular Biology
2017-today Lecturer in the School of Specialization in Infectious Diseases, teaching: Molecular Biology
2016-2019 Lecturer in the Degree Course in Physiotherapy, Biomedical and Human Preclinical Sciences (Genetics module).
2014-2017 Lecturer in the PhD in Experimental Medicine and Medical Biotechnology - University of Milan.
2014-today Lecturer in the School of Specialization in Hematology, teaching: Medical Genetics.
2009-2018 Lecturer in the School of Specialization in Medical Genetics, holder of the course: Molecular Genetics.
2009-present Lecturer in the School of Specialization in Allergology and Clinical Immunology, teaching: Medical Genetics and Molecular Biology.
2009-2016 Lecturer in the Degree Course in Medicine and Surgery, teaching of Semeiotics and Pathology of Apparatus (module of Medical and Molecular Genetics), University of Milan.
2009-2016 Lecturer in the Specialized Degree Course in Medical Biotechnology and Molecular Medicine, teaching of Genetic and Molecular Bases of Diseases-University of Milan.
2005-2013 Lecturer in the Research Doctorate in Experimental Hematology - University of Milan.
2002-2012 Teacher in the Degree Course in Medical Radiology Technician, for images and radiotherapy. Integrated course of Chemistry, Biochemistry, Biology and Genetics. Teachings of Biology and Genetics (SSD BIO13, MED03). Poli Lita and Torri-University of Milan.
2005-2009 Lecturer in the Specialized Degree Course in Medical Biotechnology and Molecular Medicine, teaching of Medical and Molecular Genetics-University of Milan.
2002-2007 Lecturer in the Degree Course in Medicine and Surgery, teaching of Semeiotics and Systematics I (module of Medical and Molecular Genetics), University of Milan.
2004-2006 Lecturer in the School of Specialization in Internal Medicine II, holder of the course: Molecular Pathology.
2002-2004 Lecturer in the Degree Course in Medicine and Surgery, Elective Course of ONCOGENOMICS, University of Milan
2004 Lecturer in the Degree Course in Medicine and Surgery, Elective Course of LABORATORY OF MEDICAL GENETICS, University of Milan
2004 Lecturer in the School of Specialization in Medical Genetics, holder of the course: Genetic predisposition to tumors.

Organisational / managerial skills

- 2014-today Responsible for UNIMI of a Scientific Agreement with the Niguarda Cancer Center (Hematology Division of the Niguarda-Milan Hospital, director Dr. Cairoli R.).
  2009-today Member of the Council of the School of Specialization in Allergology and Clinical Immunology.
  2017-today Member of the Council of the School of Specialization in Infectious Diseases
  2014-2017 Member of the Council of the Doctoral School in Experimental Medicine and Medical Biotechnology.
  2014-2018 Member of the Council of the School of Specialization in Experimental Hematology
  2009-2018 Member of the Council of the School of Specialization in Medical Genetics.
  2013-2014 Secretary of the Doctoral School in Clinical and Experimental Biomedical Sciences, University of Milan.
  2014 External reviewer in the context of a call of the University of Milan Bicocca for a research grant (candidate Gabriele Riva).
  2005-2013 Member of the Council of the Doctoral School in Experimental Hematology.

Job-related skills

- 2015 Synlab Italia-scientific consulting contract
  2014 Diasorin - consulting contract "evaluation of molecular assays with QLAMP technology"
  2011-2013 Biorad Italia - QPCR presentations at the "Bio-Rad real-time PCR" courses.
  2007-2015 Responsible for the mutational screening activities of the KIT gene in Acute Myeloid Leukemia, Chronic Eosinophilic Leukemia and Systemic Mastocytosis at the Department of Medical Biotechnology and Translational Medicine-via Viotti 5, Milan.

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem solving
Proficient user	Proficient user	Proficient user	Proficient user	Proficient user

Other skills

Replace with other relevant skills not already mentioned. Specify in what context they were acquired. Example:

- carpentry

ADDITIONAL INFORMATION

Projects

Characterization of the molecular mechanisms of activation of WNT10B signaling in AC133bright cell fractions in myeloid and lymphoid leukhemogenesis.
In collaboration with:
• S.C. of Hematology, Niguarda Cancer Center, Milan (Dr. Roberto Cairoli)

Molecular evaluation of drug-interference of Wnt-signaling by porcupine inhibitors in positive contexts for the WNT10BR allele.
In collaboration with:
• S.C. Hematology, Niguarda Cancer Center, Milan (Dr. Roberto Cairoli)
• Novartis Farma S.p.A.
• Department of Biosciences, University of Milan (Prof. Luca Del Giacco).

Application of new proximity ligation (PLA) methodologies through high-throughput strategies.
In collaboration with:
• Department of Immunology, Genetics and Pathology, SciLifeLab, Biomedical Center, Uppsala University, Uppsala, Sweden. (Prof. Ola Söderberg)

© European Union, 2002-2018 | europass.cedefop.europa.eu

Memberships

From 1/04/2021 Editor-in Chief dell'**Atlas of Genetics and Cytogenetics in Oncology and Haematology** section of Genes/Cell Biology/Cancer-Prone Diseases. (http://atlasgeneticsoncology.org)

From 2002 to present Member of the Italian Society of Human Genetics (SIGU)
From 2004 to present Member of the Editorial Board of the Atlas of Genetics and Cytogenetics in Oncology and Hematology.
(Http://atlasgeneticsoncology.org/BackpageAbout.html#EDITORIAL).

Invited speaker

20/05/2021 Speaker at the V ISCCA Congress: **"Detection of Wnt ligand-receptor interaction in leukemic stem cell by proximity ligation assay combined with flow cytometry"**.
28/10/2015 Speaker at the "Visiting Professor at DISS" meeting: "Activation of regenerative function in human tumors: too much of a Wnt thing". Department of Health Sciences, University of Milan.
15/03/2014 Speaker at the Niguarda Cancer Center Symposia E.C.M.- "From research to clinical practice: innovative therapeutic strategies in hematology". Title of the Report: "Genomic Landscapes of the LAM: mutational profiles and new paradigms". Interview: https://www.youtube.com/watch?v=_rzKsAMfpiE
01/13/2014 Speaker at the 2nd E.C.M. Course "Lessons in Clinical Hematology: Non-Hodgkin's T lymphocyte-derived lymphomas", Palace Hotel Como. Title of the Report: "New molecular markers in LNH derived from T lymphocyte derivation".
2007-2013 Speaker at the Theoretical-practical courses on "Real-Time PCR technology", at the Biorad-Segrate laboratories, Milan.
1/04/2011 Speaker at the AVIS-ADMO Conference, VII Training Course in E.C.M.- "Biodiversity at the service of Health", Manzoni Hospital, Lecco. Title of the report: "individual diversity: perspectives and applications of the knowledge acquired in genetics".
2007 Speaker at the course "Genomic research and proteomics; synergies between technologies ", at the Biorad-Segrate laboratories, Milan.
11/15/2007 Speaker at the course aimed at professional development in clinical allergology: "Mastocytosis: genetic aspects" at the Niguarda Ca'Granda-Milan Hospital.
10/11/2006 Speaker at the "Acute Myeloid Leukemia Therapy" Refresher Course at the Niguarda Ca'Granda Hospital-Milan-10 November 2006.
Published: Molecular events in Acute Myeloid leukemogenesis: a model from core binding factor leukemia.
A.Beghini
Haematologica (reports) 2 (16): 41-42, 2006
2003 Speaker at the "C.Besta" Neurological Institute of Milan, as part of a seminar entitled: "Alterations of the 19q13 region in glioblastomas induce over-expression of a new gene (MARK4), up-regulated in human gliomas and implicated in the glial differentiation ".
28/09/2002 Lecturer at the Refresher Course of the SIGU Oncology group (SIGU-ONC) entitled: Methodological Approaches in oncological genetics held at the Faculty of Medicine and Surgery, University of Verona.

Scientific reviewer

26/01/2002 Lecturer at the Refresher Course of the SIGU Oncology group (SIGU-ONC) entitled: Diseases with DNA repair defects held at the II Faculty of Medicine and Surgery of the University "La Sapienza" of Rome.

2022 Reviewer for the journal ***Blood Cancer Journal***
2021 Reviewer for the journal ***Cancers***
2020 Reviewer for the journal ***Leukemia***
2017 Reviewer of research projects for the Dutch Cancer Society (KWF Kankerbestrijding). https://www.kwf.nl/english/pages/default.aspx
2017 Section Editor (Wnt pathway) of the Atlas of Genetics and Cytogenetics in Oncology

and Hematology. (Http://atlasgeneticsoncology.org/)
2016 Reviewer for the Stem Cells magazine.
2015 Reviewer for the journal Leukemia and Stem Cells.
2014 Reviewer for the Haematologica magazine.
2012 Auditor of the ANVUR for the evaluation of research products within the VQR 2004-2010.
2011 Reviewer for The International Journal of Biochemistry & Cell Biology.
2010 Reviewer of research projects, calls of the Ministry of Health - Directorate General of Scientific and Technological Research - AIDS CALL.
2009 Reviewer for the journal Neoplasia.
2008 Reviewer for the Leukemia magazine.
(Http://www.nature.com/leu/index.html)
2006 Reviewer for the BMC Biology magazine.
(Http://www.biomedcentral.com/bmcbiol/)

Courses

2004 reviewer for the Medical Science Monitor (MSM) magazine, (www.MedSciMonit.com).
2004 Editorial Board member of the Atlas of Genetics and Cytogenetics in Oncology and Hematology. (Http://atlasgeneticsoncology.org/).
2003 reviewer for the journal Endocrine-Related Cancer, Bristol, UK.

November 23, 2011 Workshop: CellProfiler: cell image analysis software (Prof. C.Wählby), Uppsala University, Uppsala, Sweden.
12-15 September 2002 8th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumors, Barcelona, Spain.

Pubblications

21-22 September 2001 European COST Action B19, WG5 on the theme: "Molecular Cytogenetics of Solid Tumors", Verbania, Italy
21-26 January 2001 Gordon Conference on the theme: "RNA editing", Ventura, CA, USA.
7-10 October 1999 EMBO Workshop on the theme: "Stem Cells, Growth Factors and Cancer" Castle of Stupinigi, (Turin).

1. A novel start-loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms.
Beghini A., Leuzzi L., Abazari N., Bossi L.E., Guido V., Trojani A., Cairoli R.
Hematol Oncol: 2022; 1-4, doi: 10.1002/hon.3023

2. Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to smoldering/Symptomatic Waldeström Macroglobulinemia (WM) by a comparative transcriptome analysis of B cells and Plasma cells.
Trojani A., Di Camillo B., Bossi L.E., Leuzzi L., Greco A., Tedeschi A., Frustaci A.M., Deodato M., Zamprogna G., **Beghini A.**, Cairoli R.
Cancers: 2021; 13(8): 1837, doi.org/10.3390/cancers13081837

3. FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T cell acute lymphoblastic leukemia.
Cassaro A., Grillo G., Notaro M., Gliozzo J., Esposito I., Reda G., Trojani A., Valentini G., Di Camillo B., Cairoli R., **Beghini A.**
Hematological Oncology: 2021 in press

4. CSNK2A2 (casein kinase 2 alpha 2)
Abazari N., **Beghini A.**
Atlas Genet Cytogenet Oncol Haematol: 2020 in press.
http://atlasgeneticsoncology.org//Genes/GC_CSNK2A2.html

5. Targeting WNT10B-driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia.
Cassaro A., Lazzaroni F., Grillo G., Reda G., Cairoli R., **Beghini A**.
Blood: 134 (Suppl._1) 2019.
http://dx.doi.org/10.1182/blood-2019-124871

6. Core binding factor leukemia: chromatin remodeling moves towards oncogenic transcription.

Beghini A.
Cancers (Basel): 11(12):1973, 2019
DOI : http://dx.doi.org/10.3390/cancers11121973

7. FZD6 (Frizzled class receptor 6)
Beghini A., Postorino G.
Atlas Genet Cytogenet Oncol Haematol: 23(5):112-119, 2019.
DOI : https://doi.org/10.4267/2042/70206

8. FZD4 (Frizzled class receptor 4)
Beghini A., Cassaro A.
Atlas Genet Cytogenet Oncol Haematol, 22(8):317-322, 2018.
DOI : https://doi.org/10.4267/2042/68929

http://AtlasGeneticsOncology.org/Genes/FZD4ID40655ch11q14.html

9. WNT10B (Wingless-Type MMTV Integration Site Family).
Beghini A., Lazzaroni F.
Atlas Genet Cytogenet Oncol Haematol, 21(11):398-403, 2017
DOI : https://doi.org/10.4267/2042/68996

10. Intronless WNT10B-short variant underlies new recurrent allele-specific rearrangement in acute myeloid leukemia
Lazzaroni F., Del Giacco L., Biasci D., Turrini M., Prosperi L., Brusamoilino R., Cairoli R., **Beghini A**.
Scientific Reports: 6:37201, 2016. doi: 10.1038/srep37201
Corrigendum: *Scientific Reports* 2017 Apr 26;7:46788. doi: 10.1038/srep46788
Highlighted in Oggiscienza: https://oggiscienza.it/2016/11/29/leucemia-mieloide-acuta-sequenza-non-umana/

11. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J., Rossetti S., Datta A., Eng K.H., **Beghini A.**, Sacchi N.
Molecular Cancer 14(1): 7, 2015. doi: 10.1186/s12943-014-0283-z
Highlighted on Global Medical Discovery: https://globalmedicaldiscovery.com/key-scientific-articles/mir-17-deregulates-a-core-runx1-mirna-mechanism-of-cbf-acute-myeloid-leukemia/

12. Identification of KIT^{M541L} somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.
Iurlo A., Gianelli U., **Beghini A.**, Spinelli O., Orofino N., Lazzaroni F., Cambiaghi S., Intermesoli T., Rambaldi A., Cortelezzi A.
Oncotarget: 5(13); 4665-4670, 2014

13. Successful treatment with imatinib in a patient with chronic eosinophilic leukemia, not otherwise categorized.
Iurlo A., Fracchiolla N.S., Ferla V., Cassin R., Gottardi E., **Beghini A.**, Gianelli U., Spinelli O., Cortelezzi A.
J Clin Oncol: 32(10); e37-39, 2014

14. Old and new prognostic factors in acute myeloid leukemia with deranged core-binding factor beta.
Cairoli R., **Beghini A.**, Turbini M., Bertani G., Nadali G., Rodeghiero F., Castagnola C., Lazzaroni F., Nichelatti M., Ferrara F., Zizzolo G., Pogliani E., Rossi, G., Martinella G., Morra E.
Am J Hematol: 88(7); 594-600, 2013

15. PTPN6 (Protein tyrosine phosphatase, non-receptor type 6).
Beghini A, Lazzaroni F.
Atlas Genet Cytogenet Oncol Haematol, 2013
URL: http://AtlasGeneticsOncology.org/Genes/PTPN6ID41920ch12p13.html

16. Regeneration-associated Wnt signaling is activated in long-term reconstituting $AC133^{bright}$ acute myeloid leukemia cells.
Beghini A, Corlazzoli F., Del Giacco L., Re M., Lazzaroni F., Brioschi M., Valentini G., Ferrazzi F., Ghilardi A., Righi M., Turrini M., Mignardi M., Cesana C., Bronte V., Nilsson M., Morra E., Cairoli R.

Neoplasia: 14(12): 1236-1248, 2012.

17. Prognostic markers in AML: focus on CBFL.
Cairoli R., **Beghini A.**, Turrini M., Bertani G., Morra E.
Leukemia Supplements: 1: S12-S13, 2012.

18. A mathematical model for the validation of gene selection methods.
Muselli M., Bertoni A., Frasca M., **Beghini A.**, Ruffino F., Valentini G.
IEEE/ACM Trans Comput Biol Bioinform.: 8(5): 1385-1392, 2011.

19. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core binding factor subunits.
Brioschi M., Fischer J., Cairoli R., Rossetti S., Pezzetti L., Nichelatti M., Turrini M., Corlazzoli F., Scarpati B., Morra E., Sacchi N., **Beghini A.**
Neoplasia: 12(11): 866-876, 2010.

20. PTPN13 (Protein tyrosine phosphatase, nonreceptor type 13).
Beghini A.
Atlas Genet Cytogenet Oncol Haematol. 13(8): 573-575, 2009.
URL : http://AtlasGeneticsOncology.org/Genes/PTPN13ID41912ch4q21.html

21. A stability-based algoritm to validate hierarchical clusters of genes.
Avogadri R., Brioschi M., Ferrazzi F., Re M., **Beghini A.**, Valentini G.
Int. J. Knowledge Engineering and Soft Data Paradigms: 1(4): 318-330, 2009.

22. Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia.
Cairoli R., Ripamonti C.B., **Beghini A.**, Granata S., Grillo G., Brioschi M., Nadali G., Viola A., Cattaneo C., Inropido L., Ravelli E., Bertani G., Pezzetti L., Nichelatti M., Marocchi A., Rossi G., Pizzolo G., Ferrara F., Nosari A.M., Morra E.
Leukemia Research: 33(9):1282-4, 2009.

23. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukemias with KIT or FLT3 mutation.
Trojani A., Ripamonti C.B., Penco S., **Beghini A.**, Nadali G.P., di Bona E., Viola A., Castagnola C., Colapietro P., Grillo G., Pezzetti L., Ravelli E., Patrosso M.C., Marocchi A., Cuneo A., Ferrara F., Lazzarino M., Pizzolo G., Cairoli R., Morra E.
Anticancer Research: 28: 2745-2752, 2008.

24. KIT mutations in core binding factor leukemias: outcome prediction and therapeutic implications.
Cairoli R., **Beghini A.**, Grillo G., Nadali G., Elice F., Ripamonti C.B., Colapietro P., Nichelatti M., Pezzetti L., Cuneo A., Viola A., Cattaneo C., Rossi A., Ferrara F., Castagnola C., Lazzarino M., Rodeghiero F., Zizzolo G., Larizza L., Morra E.
Haematologica (reports) 2(16): 43-46, 2006.

25. Molecular events in Acute Myeloid leukemogenesis: a model from *core binding factor* leukemia.
Beghini A.
Haematologica (reports) 2(16): 41-42, 2006.

26. Distinct expression pattern of microtubule-associated protein/microtubule affinity-regulating kinase 4 in differentiated neurons.
Moroni R.F., De Biasi S., Colapietro P., Larizza L., **Beghini A.**
Neuroscience: 143: 83-94, 2006.

27. Prognostic impact of c-KIT mutations in Core Binding Factor Leukemias. An Italian retrospective study.
Cairoli R., **Beghini A.**, Grillo G., Nadali G., Elice F., Ripamonti C.B., Colapietro P., Nichelatti M., Pezzetti L., **Lunghi M.**, Cuneo A., Viola A., Ferrara F., **Lazzarino M.**, Rodeghiero F., Pizzolo G., Larizza L., Morra E.
Blood: 107(9):3463-8, 2006.

28. Identification of oligodendroglioma specific chromosomal copy number changes by array-CGH and FISH analysis in the glioblastoma MI-4 cell line.
Magnani I., Moroni R.F., Roversi G., **Beghini A.**, Pfundt R., Schoenmakers E.F., Larizza L.

Cancer Genet Cytogenet: 161(2):140-5, 2005.

29. STI 571 inhibition effect on KIT^{Asn822Lys}-mediated signal transduction cascade
Beghini A., Bellini M., Magnani I., Colapietro P., Cairoli R., Morra E., Larizza L
Experimental Hematology: 33(6): 682-688, 2005.

30. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations: A report of three cases.
Cairoli R., **Beghini A.**, Morello F., Grillo G., Montillo M., Larizza L., Morra E.
Leukemia Research: 29(4): 397-400, 2005.

31. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukaemia
Larizza L., Magnani I., **Beghini A.**

Leukemia & Lymphoma: 46(2): 247-255, 2005 (Review).

32. KIT activating mutations: incidence in adult and pediatric AML, and identification of an internal tandem duplication
Beghini A., Ripamonti CB., Cairoli R., Cazzaniga G., Colapietro P., Elice F., Nadali G., Grillo G., Haas O.A., Biondi A., Morra E., Larizza L.

Haematologica: 89(8): 920-925, 2004.

33. Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis.
Cairoli R, Grillo G, **Beghini A**, Cornacchini G, Larizza L, Morra E.
The Hematology Journal 5(3):273-5, 2004.

34. MARK4 (MAP/microtubule affinity-regulating kinase 4).
Beghini A.
Atlas Genet Cytogenet Oncol Haematol. 7(3): 164-165, 2003.
URL : http://AtlasGeneticsOncology.org/Genes/MARK4ID419.html

35. AML with t(8;21) and trisomy 4: possible involvement of c-kit?
Langabeer SE, **Beghini A**, Larizza L.
Leukemia. 17(9):1915, 2003.

36. RNA processing defects of the helicase gene *RECQL4* in a compound heterozygous Rothmund Thomson patient.
Beghini A., Castorina P., Roversi G., Modiano P., Larizza L.
Am. J. Med. Genet. 120A:395-399, 2003.

37. The neural progenitor-restricted isoform of the *MARK4* gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines.
Beghini A., Magnani I., Roversi G., Piepoli T., DiTerlizzi S., Moroni R.F., Pollo B., Conti A.M.F., Cowell J.K., Finocchiaro G., Larizza L.
Oncogene 22:2581-2591, 2003.

38. Identification of two novel RECQL4 exonic SNPs and genomic characterization of the IVS12 minisatellite.
Roversi G., **Beghini A.**, Zambruno G., Paradisi M., Larizza L.
J. Hum. Genet 48: 107-109, 2003.

39. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index.
Cairoli R., Grillo G., **Beghini A.**, Tedeschi A., Ripamonti C.B., Larizza L., Morra E.
Leukemia 17: 471-472, 2003.

40. RECQL4 (RecQ protein-like 4).
Beghini A.
Atlas Genet Cytogenet Oncol Haematol. 6(1): 21-22, 2002.
URL : http://AtlasGeneticsOncology.org/Genes/RECQL4ID285.html

41. Rothmund-Thomson syndrome (RTS).

Beghini A, Larizza L.
Atlas Genet Cytogenet Oncol Haematol. 6(1): 56-58, 2002.
URL : http://AtlasGeneticsOncology.org/Kprones/RothmundID10021.html

42. An unusual mutation in RECQ4 gene leading to Rothmund-Thomson syndrome
Balraj P., Concannon P., Jamal R., **Beghini A.**, Hoe T.S., Khoo A.S., Volpi L.
Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 508: 99-105, 2002.

43. Amplification of a novel c-Kit activating mutation Asn^{822}-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.
Beghini A., Magnani I., Ripamonti C.B., Larizza L..

The Hematology Journal 3: 157-163, 2002.

44. Germline mutation in the juxtamembrane domain of KIT gene in a family with GISTs and Urticaria Pigmentosa
Beghini A., Tibiletti M.G., Roversi G, Chiaravalli A.M., Serio G, Capella C, Larizza L.

Cancer 92:657-62, 2001.

45. +4 or trisomy 4.
Beghini A.
Atlas Genet Cytogenet Oncol Haematol. 4(3): 129-130 2000.
URL : http://AtlasGeneticsOncology.org/Anomalies/tri4ID1011.html

46. Piebaldism.
Larizza L, **Beghini A**.
Atlas Genet Cytogenet Oncol Haematol. 4(3): 157-158, 2000.
URL : http://AtlasGeneticsOncology.org/Kprones/piebaldID10030.html

47. Familial /sporadic gastrointestinal stromal tumors (GISTs).
Larizza L, **Beghini A**.
Atlas Genet Cytogenet Oncol Haematol. 4(3): 155-156, 2000.
URL : http://AtlasGeneticsOncology.org/Kprones/GastroISTID10029.html

48. Systemic mast cell disease (SMCD).
Larizza L, **Beghini A**.
Atlas Genet Cytogenet Oncol Haematol. 4(3): 125-126, 2000
URL : http://AtlasGeneticsOncology.org/Anomalies/MastCellID2064.html

49. KITLG (KIT ligand).
Larizza L, **Beghini A**.
Atlas Genet Cytogenet Oncol Haematol. 4(3): 99-100, 2000.
URL : http://AtlasGeneticsOncology.org/Genes/MGFID142.html

50. KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog).
Larizza L, **Beghini A**.
Atlas Genet Cytogenet Oncol Haematol. 4(3): 96-98, 2000.
URL : http://AtlasGeneticsOncology.org/Genes/KITID127.html

51. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia
Beghini A., Ripamonti C.B., Peterlongo P., Roversi G., Cairoli R., Morra E., Larizza L.

Human Molecular Genetics 9(15): 2297-2304, 2000.

52. C-kit mutations in core binding factor leukemias
Beghini A., Cairoli R., Peterlongo P., Ripamonti CB., Mecucci C., Morra E., Larizza L.
Blood 95(2):4-5, 2000.

53. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement.
Beghini A., Ripamonti C., Castorina P., Pezzetti L., Doneda L., Cairoli R., Morra E., Larizza L.
Cancer Genetics and Cytogenetics. 119: 26-31, 2000.

54. C-kit activating mutations and mast cell proliferation in human leukemia.
Beghini A., Larizza L., Cairoli R., Morra E.
Blood 92(2): 701-702, 1998.

55. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation.
Beghini A., Cairoli R., Morra E., Larizza L.
Blood Cells, Molecules & Diseases 24(2): 262-70, 1998.

56. Microsatellite instability in IVS3 of murine *c-fes* gene: tumor-associated rearrangement and mammalian divergente.
Volpi L., **Beghini A.**, Rossi D., Larizza L.
Mammalian Genome 7(9): 682-5, 1996.

Abstract in rivista

57. Impact of KIT mutations in acute myeloid leukaemia with inv(16).
R. Cairoli, **A. Beghini**, C.B. Ripamonti, G. Grillo, G. Nadali, E. Di Bona, P. Colapietro, G.B. Bertani, E. Ravelli, G. Nador, C. Castagnola, C Cattaneo, E. Ottaviani, P. Pioltelli, A. Viola, A. Cuneo, F. Ferrara, G. Martinelli, M. Lazzarino, G. Rossi, G. Pizzolo, E. Morra
Haematologica: **93**: 16, 2008.

58. Molecular screening of PDGFRA and PDGFRB genes in KIT and FLT3 negative core binding factor leukemias.
R. Cairoli, A. Trojani, C.B. Ripamonti, S. Penco, **A. Beghini**, G.P. Nadali, F. Elice, A. Viola, C. Castagnola, P. Colapietro, G. Grillo, P. Pezzetti, E. Ravelli, A. Marocchi, M.C. Patrosso, A. Cuneo, F. Ferrara, F. Rodeghiero, M. Lazzarino, G. Pizzolo, E. Morra
Haematologica: **92**: 486, 2007.

59. Prevalence and prognostic impact of KIT mutations in acute myeloid leukaemia with inv(16). A retrospective study.
R. Cairoli, **A. Beghini**, C.B. Ripamonti, G. Grillo, G. Nadali, E. Di Bona, P. Colapietro, M. Nichelatti, G. Bertani, E. Ravelli, A. Cuneo, E. Ottaviani, P. Pioltelli, F. Ferrara, M. Lazzarino, G. Rossi, F. Rodeghiero, G. Pizzolo, G.N. Martinelli, E. Morra.
Blood: **110**: 1021A-1022A, 2007.

60. Serum tryptase levels in AML at diagnosis : a multicenter retrospective study.
R. Cairoli, C.B. Ripamonti, S. Granata, **A. Beghini**, P. Colapietro, G. Grillo, G. Nadali, A. Viola, C. Cattaneo, L. Intropido, E. Ravelli, G. Bertani, L. Pezzetti, M. Nichelatti, S. Veronese, A. Marocchi, G. Rossi, G. Pizzolo, F. Ferrara, A. Nosari, E. Morra.
Blood: **108**: 668A, 2006.

61. Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia.
R. Cairoli, **A. Beghini**, G. Nadali, F. Elice, M. Lunghi, A. Cuneo, G. Grillo, M. Michelatti, C.B. Ripamonti, M. Lazzarino, F. Rodeghiero, G. Pizzolo, L. Larizza, E. Morra.
Blood: **104**: 555A, 2004.

62. C-KIT mutations are relatively frequent event in progression of AML M2.
A. Beghini, R. Cairoli, P. Peterlongo, C: Ripamonti, C. Mecucci, E. Morra, L. Larizza.
Haematologica: **84**(9) suppl.: 14, 1999

63. Systemic mast cell disease and prognostic role of c-KIT mutations.
A. Beghini, C. Ripamonti, L. Pezzetti, R. Cairoli, A. Belloni, A. Pesarico, E.M. Pogliani, E. Morra, L. Larizza.
Haematologica: **84**: 82, 1999.

64. High frequency of c-kit mutation in core binding factor leukemia.
A. Beghini, R. Cairoli, P. Peterlongo, C. Ripamonti, C. Mecucci, L. Pezzetti, E. Morra, L. Larizza.
Blood: **94**: 200B, 1999.

65. In vivo differentiation of mast cells from AML M2 blasts carrying a novel activating ligand-independent c-KIT mutation.
A. Beghini, R.Cairoli, E.Morra, L. Larizza.
Br.J.Haematol.: **102**(1): O-0048, 1998.

66. Trisomy 4 and c-KIT mutation in a t(8;21) myeloid leukemia with mast cell involvement.
A. Beghini, P. Castorina, R. Cairoli, C. Ripamonti, E. Morra, L. Larizza
Cytogenet. Cell Genet.: **81**(2): 148, 1998.

67. Detection of c-KIT antigen (CD117) and c-KIT mRNA in Acute Leukemia
R. Cairoli, P. Riva, L. Pezzetti, **A. Beghini**, L. Intropido, S. Romagnoli, S. Danieli, A.F. Conti, M. Volontè, E. Morra, L.Larizza.
Exp.Haematol.: **24**(9): 550, 1996.

Contributo in Atti di convegno

68. An algorithm to assess the reliability of hierarchical clusters in gene expression data.
R. Avogadri, M. Brioschi, F. Ruffino, F. Ferrazzi, **A. Beghini**, G. Valentini
In: 12° International Conference, KES 2008 : Pt. 2. Zagreb (Croatia),
Knowledge-Based Intelligent Information and Engineering Systems: p. 764-770, Berlin SPRINGER, 2008.

69. Characterization of the Kasumi-1 cell line as a t(8;21)-Kit mutant model for core binding factor leukemia.
Beghini A, Magnani I, Ripamonti CB, Larizza L
In: 7th Annual Meeting of the European Haematology Association. Firenze, 6-9 Giugno 2002 p. 147-156, BOLOGNA Monduzzi Editore 2002.

Personal information

I authorize the handling of personal information in this curriculum, according to D.Lgs n. 196/03 and following modifications and Regulations EU 679/2016 (General Regulations concerning Data Protection or GRDP) and art. 7 of University Regulations concerning protection of personal information.

I authorize, according to D.lgs 14/03/2013 n. 33 concerning transparency, in case of conferment of the position and of the fellowship, the publication of this curriculum in the web site of Università degli Studi di Milano in the section "Amministrazione trasparente", "Consulenti e collaboratori".

Date: 22/01/2021

Signature